CD274 and gastric cancer: Although PD-L1 expression in GC has been associated with poorer outcomes, anti-PD-L1 antibodies (e.g., atezolizumab, avelumab, durvalumab) and anti-PD-1 antibodies (e.g., nivolumab, pembrolizumab) have been shown to improve OS in patients with advanced or metastatic GC [63,64].